Autoinflammatory & rare systemic diseases
B cell depletion after treatment with rituximab predicts relapse of IgG4-related disease
Authors' conclusion
The degree of B cell depletion 6 months after rituximab may predict disease flare and may instruct on the pacing of B cell depletion therapy in IgG4-RD.
Study context
- Population
- Patients with active IgG4-related disease (IgG4-RD) fulfilling the ACR/EULAR Classification Criteria, treated with two 1 g RTX infusions 15 days apart, monitored 48 months
- Participants
- 33 patients
- Exposure
- Complete vs incomplete B cell depletion 6 months after RTX
- Outcome
- Relapse of IgG4-RD by B cell depletion status 6 months after RTX
- Follow-up
- 48 months
Main finding
As reported in the abstract
Relapse rate by CD19+ B cell depletion · 6 months after RTX
P = 0.02
Observational data: associations, not effects.
Further findings
| Outcome | Complete depletion | P value |
|---|---|---|
| Relapse rate by naïve B cell depletion · 6 months after RTXIncomplete depletion vs Complete depletion | 15% | P = 0.01 |
| Relapse rate by memory B cell depletion · 6 months after RTXIncomplete depletion vs Complete depletion | 16% | P = 0.03 |
| Median relapse-free survival by CD19+ B cell depletionIncomplete depletion vs Complete depletion | median 38 months | P = 0.02 |
| Median relapse-free survival by naïve B cell depletionIncomplete depletion vs Complete depletion | median 38 months | P = 0.01 |
| Median relapse-free survival by memory B cell depletionIncomplete depletion vs Complete depletion | median 38 months | P = 0.03 |
- Relapse rate by naïve B cell depletion: Incomplete depletion 54%
- Relapse rate by memory B cell depletion: Incomplete depletion 50%
- Median relapse-free survival by CD19+ B cell depletion: Incomplete depletion median 19 months
- Median relapse-free survival by naïve B cell depletion: Incomplete depletion median 16 months
- Median relapse-free survival by memory B cell depletion: Incomplete depletion median 19 months
Overall relapses · median 24 months after RTX
- Relapses (all patients)
- 23 (70%)
- Disease response at 6 months
- all patients
- Complete depletion of CD19+ B cells, plasmablasts, naïve and memory B cells
- 30%, 55%, 39%, 42%
Original publication
B cell depletion after treatment with rituximab predicts relapse of IgG4-related disease. Rheumatology (Oxford). Published 23 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →